During the Association for Accessible Medicine’s meeting, which took place Feb. 5, leaders of the trade group emphasized that generic companies needed to increase the amount of time they spend with lawmakers and how much money they spent lobbying for policies that better suit generic makers.
In 2018, generic drug companies spent significantly less on lobbying than brand-name drug companies. For example, brand-name drugmakers Pfizer and Amgen spent $11.4 million and $10.9 million respectively. This compares to Mylan, which spent 2.9 million and Teva which spent $2.6 million.
“The risks at the federal level as well as at the state level where the generic industry has historically been under-represented are real,” Chip Davis, head of the Association for Affordable Medicine, told drug company representatives at the meeting.
More articles on pharmacy:
Senate committee invites 7 pharma leaders to testify at drug price hearing
4 big pharma CEOs agree to testify at February drug-pricing hearing
Walgreens pays nearly $2M to settle claims with MassHealth
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
